Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.

Alex K. Bryant,Huiying Yin,Matthew J. Schipper,P.A. Paximadis,T.P. Boike,D P Bergsma,Benjamin Movsas,Munther Ajlouni,Robert T. Dess,Melissa A. Mietzel,Randi Kendrick,Merita Seferi,Michael M. Dominello,Martha M. Matuszak,Reshma Jagsi,James A. Hayman,Lori J. Pierce,Shruti Jolly

Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.

2021

Alex K. Bryant
Huiying Yin
Matthew J. Schipper
P.A. Paximadis
T.P. Boike
D P Bergsma
Benjamin Movsas
Munther Ajlouni
Robert T. Dess
Melissa A. Mietzel
Randi Kendrick
Merita Seferi
Michael M. Dominello
Martha M. Matuszak
Reshma Jagsi
James A. Hayman
Lori J. Pierce
Shruti Jolly

8523Background: In the landmark PACIFIC trial, adjuvant durvalumab after definitive chemoradiation for unresectable stage III non-small-cell lung cancer (NSCLC) produced a 11% absolute overall surv...

Keywords:

Adjuvant
Durvalumab
Lung cancer
Medicine
Oncology
Stage III Non-Small Cell Lung Cancer
Stage (cooking)
Internal medicine
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations